-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
-
Summary
-
Inhibitor Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from 2012 to Q1 2025.
- Inhibitor Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2025 was -$1.28M, a 11% decline year-over-year.
- Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$3.23M, a 19.7% decline from 2023.
- Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$2.7M, a 123% decline from 2022.
- Inhibitor Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $11.7M.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)